QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
NYSEAMERICAN:ASXC

Asensus Surgical (ASXC) Stock Price, News & Analysis

$0.29
0.00 (0.00%)
(As of 02/22/2024 ET)
Today's Range
$0.28
$0.29
50-Day Range
N/A
52-Week Range
$0.20
$0.96
Volume
906,544 shs
Average Volume
1.12 million shs
Market Capitalization
$76.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.50

Asensus Surgical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
417.2% Upside
$1.50 Price Target
Short Interest
Bearish
6.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.97mentions of Asensus Surgical in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$5,078 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.32) to ($0.19) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.59 out of 5 stars


ASXC stock logo

About Asensus Surgical Stock (NYSEAMERICAN:ASXC)

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

ASXC Stock Price History

ASXC Stock News Headlines

Porter Stansberry exposes $100 billion hoax
: Artificial Illusion They say it’s the “biggest advancement in modern history…” But THEY’RE WRONG. Artificial intelligence is an Artificial Illusion. Which means if you own AI stocks, you need to watch this film now before it’s too late.
Asensus Surgical (ASXC) Completes Surgeon Lab for LUNA
Clear Buy, Sell, or Hold Recommendation on any Stock, FREE
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Asensus Surgical Announces Sale Of Senhance Surgical System In Romania
Senhance Robotic System Sold by Asensus Surgical
See More Headlines
Receive ASXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Asensus Surgical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
2/22/2024
Next Earnings (Estimated)
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:ASXC
CIK
N/A
Employees
183
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.50
High Stock Price Target
$2.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+423.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-75,560,000.00
Net Margins
-1,409.77%
Pretax Margin
-1,405.67%

Debt

Sales & Book Value

Annual Sales
$7.09 million
Book Value
$0.42 per share

Miscellaneous

Free Float
256,731,000
Market Cap
$75.75 million
Optionable
Not Optionable
Beta
1.43
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Anthony FernandoMr. Anthony Fernando (Age 52)
    President, CEO & Director
    Comp: $901.03k
  • Mr. Shameze Rampertab B.Sc. MBA (Age 57)
    CA, CPA, Executive VP & CFO
    Comp: $511.25k
  • Mr. Joshua B. Weingard (Age 51)
    Chief Legal Officer & Secretary
  • Mr. Paul Ziegler Jr. (Age 51)
    J.D., Vice President of Sales
  • Mr. Ethan Loiselle
    Vice President of Global Marketing
  • Ms. Amanda Owens
    Vice President of People
  • Mr. Ravi Kommineni
    Head of Global Quality & Regulatory
  • Mr. Motti Frimer
    Vice President of R&D, Digital Solutions and MD of Asensus Surgical














ASXC Stock Analysis - Frequently Asked Questions

Should I buy or sell Asensus Surgical stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Asensus Surgical in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ASXC shares.
View ASXC analyst ratings
or view top-rated stocks.

What is Asensus Surgical's stock price target for 2024?

2 brokerages have issued 12 month price targets for Asensus Surgical's shares. Their ASXC share price targets range from $1.00 to $2.00. On average, they predict the company's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 417.2% from the stock's current price.
View analysts price targets for ASXC
or view top-rated stocks among Wall Street analysts.

Are investors shorting Asensus Surgical?

Asensus Surgical saw a decline in short interest during the month of January. As of January 31st, there was short interest totaling 17,510,000 shares, a decline of 9.8% from the January 15th total of 19,410,000 shares. Based on an average trading volume of 1,410,000 shares, the short-interest ratio is presently 12.4 days. Currently, 6.8% of the shares of the stock are short sold.
View Asensus Surgical's Short Interest
.

When is Asensus Surgical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 29th 2024.
View our ASXC earnings forecast
.

How were Asensus Surgical's earnings last quarter?

Asensus Surgical, Inc. (NYSEAMERICAN:ASXC) released its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The company earned $2.57 million during the quarter, compared to the consensus estimate of $1.02 million. Asensus Surgical had a negative trailing twelve-month return on equity of 103.62% and a negative net margin of 1,409.77%.

What guidance has Asensus Surgical issued on next quarter's earnings?

Asensus Surgical issued an update on its fourth quarter 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $5.1 million-$5.7 million, compared to the consensus revenue estimate of $3.7 million.

Who are Asensus Surgical's major shareholders?

Asensus Surgical's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.38%), Northern Trust Corp (0.19%), Simplex Trading LLC (0.00%), GTS Securities LLC (0.00%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrea Biffi, Anthony C J Fernando, David Bruce Milne, Elizabeth Kwo and William N Starling Jr.
View institutional ownership trends
.

How do I buy shares of Asensus Surgical?

Shares of ASXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:ASXC) was last updated on 2/22/2024 by MarketBeat.com Staff